Dr. Smith utilized the robot to provide visualization during the "closed-chest" procedure. With visualization and several small incisions a surgeon can perform TMR with the CO2 Heart Laser less invasively than through an open chest or thoracotomy. Such less invasive technologies provide the same benefit to patients and reduce hospital stays and recovery time.
"CO2 TMR has proven to be an effective therapy for severe angina patients", stated Dr. J. Michael Smith. "In addition, robotic-assisted technology is gaining a pivotal role in the cardiac surgical community. We believe providing this established angina relief therapy through less invasive methods will be beneficial for patients."
Tri-Health is comprised of Good Samaritan Hospital and Bethesda North Hospital; both have been providing excellent, leading-edge heart care for more than a generation. In fact, Good Samaritan Hospital was a pioneer in heart surgery, performing the first cardiac catheterization and the first open-heart surgery in a private adult hospital in Cincinnati, Ohio. Today, TriHealth continues to break new ground and is both the first to use robotics in open-heart surgery, and the first hospital in the Cincinnati region implementing a TMR laser.
PLC Systems is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Currently, the company is focused on two unique laser therapies for the treatments of severe angina and cardiac arrhythmias. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System that cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. For the cardiac arrhythmia market, PLC is developing a surgical cardiac ablation laser technology, known as the Optimaze.
Edwards Lifesciences is specialized in advanced cardiovascular disease treatments and the number-one heart valve company in the world. Headquartered in Irvine, California, Edwards focuses on four main cardiovascular disease states: heart valve disease, coronary artery disease, peripheral vascular disease and congestive heart failure. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, Swan-Ganz and Fogarty.